Hexarelin

Overview

Synthetic hexapeptide growth-hormone secretagogue acting principally through the ghrelin receptor.

Evidence quality

Source identities are PubMed-resolved and provisionally graded by study design. Full-text findings, bias, applicability, contradictions, and regulatory interpretation remain pending.

Safety concerns

Proposed uses lack mature confirmatory evidence; endocrine, cardiometabolic, product-quality, and duration limits matter.

Citations as of this version

• Growth hormone-releasing peptides.
• Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.
• Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. — Microvascular research (2022)
• Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. — Frontiers in physiology (2021)
• Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. — Drug target insights (2021)
• Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. — Canadian journal of physiology and pharmacology (2021)
• Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. — Pharmaceuticals (Basel, Switzerland) (2021)
• SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study. — Heliyon (2020)
• Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats. — Turkish journal of medical sciences (2019)
• Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE-/- mice. — Peptides (2019)
• Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy. — Die Pharmazie (2019)
• The Safety and Efficacy of Growth Hormone Secretagogues. — Sexual medicine reviews (2018)
• The CD36-PPARγ Pathway in Metabolic Disorders. — International journal of molecular sciences (2018)
• Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats. — Physiological reports (2018)
• The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway. — International heart journal (2017)
• The cardiovascular action of hexarelin. — Journal of geriatric cardiology : JGC (2014)
• We are ageing. — BioMed research international (2014)
• New active series of growth hormone secretagogues. — Journal of medicinal chemistry (2003)
• Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. — The Journal of endocrinology (2002)
• Hexarelin protects H9c2 cardiomyocytes from doxorubicin-induced cell death. — Endocrine (2001)
• Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption. — The Journal of pharmacy and pharmacology (2001)
• Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. — Drug metabolism and disposition: the biological fate of chemicals (2000)
• Hexarelin as a test of pituitary reserve in patients with pituitary disease. — Clinical endocrinology (1999)
• The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. — Clinical endocrinology (1999)
• Growth hormone in obesity. — International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity (1999)
• Does desensitization to hexarelin occur? — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (1998)
• Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. — The Journal of clinical endocrinology and metabolism (1996)

Regulatory status as of this version

• United States: not_approved
• European Union: not_approved